MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020AUTHORS:Peter W. Blumencranz, Mehran Habibi, Lisa Blumencranz, Andrea Read More
Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Read More
Differential gene expression and clinical utility of MammaPrint and BluePrint in male breast cancer patients
PUBLICATION: SABCS 2020 AUTHORS: Jennifer A. Crozier, Julie Barone, Kalyan Read More
Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer
PUBLICATION:SABCS 2020AUTHORS:Laura Lee, Sami Diab, Julie Barone, Jennifer A. Crozier, Read More
Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
PUBLICATION: SABCS 2020 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen Read More
Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Read More
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
PUBLICATION: SABCS 2020 AUTHORS:Iris Noordhoek, Esther Bastiaannet, Ersan Lujinovic, Laura Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling Read More
